Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT04690972 |
| Other study ID # |
C19-76 |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
December 20, 2020 |
| Est. completion date |
December 4, 2028 |
Study information
| Verified date |
September 2020 |
| Source |
Institut National de la Santé Et de la Recherche Médicale, France |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Development of preclinical translational models for chronic liver tumors and diseases study,
such as spheroids cultured in autologous medium and murine xenograft models to test the
efficacy of new therapeutic strategies.
Description:
The Institute for Research on Viral and Hepatic Diseases, Inserm Unit UMR_S 1110, in
Strasbourg, studies hepatic diseases such as non-alcoholic steatohepatitis (NASH),
non-alcoholic fatty liver disease (NAFLD), cirrhosis and hepatocellular carcinoma (CHC).
These diseases can be induced by hepatitis viruses, B (HBV), C (HCV) and D (VHD), but also a
poor lifestyle combining overeating and the sedentary lifestyle of our current living
patterns.
To date, no treatment is available to cure non-alcoholic steatohepatitis (NASH), cirrhosis,
and prevent the development of liver tumors. One of the reasons for the lack of specific
treatment is the limited knowledge of the pathophysiology of the liver and the hepatic
microenvironment. In addition, the heterogeneity of HCC and associated underlying liver
diseases, and the lack of adequate preclinical models are at the root of the difficulties in
identifying an effective therapeutic target for these diseases.
Thus, new molecular profiling techniques and strategies are needed to meet these medical
needs, in particular the prediction of the response to treatment of HCC, which is still
largely unsatisfactory, and the discovery of new therapeutic targets. Using innovative
approaches, UMR_S 1110 utilizes single cell RNA sequencing, which is a high resolution
technique to analyze gene expression at the individual cell level. This technique represents
the most advanced tool for studying heterogeneous tissues such as cancerous tissue.
An in-depth knowledge of HCC and the liver tumor environment at the single-cell level is
crucial for understanding the progression of liver disease, for identifying new therapeutic
targets and improving clinical outcomes by allowing for estimate the response to treatment
and thus improve the patient's vital prognosis, by offering him an adapted personalized
treatment. In order to identify factors determining hepatocarcinogenesis, predictors of
response to treatment and new therapeutic targets, the investigators propose to analyze
tissues from patients with chronic liver disease.
The investigator aim :
1. / to establish ex vivo models of chronic hepatic disease and hepatic tumors, in order to
study and validate the therapeutic targets identified in the laboratory from single cell
RNA sequencing from hepatic tissues obtained from patients. These models include
spheroid cultures and models of mice developing liver tumors from xenografts of tumors
from patients. To ensure the successful establishment of these complex models, the use
of autologous sera is necessary.
2. / profile the hepatic tumors and the hepatic tissue adjacent to the tumor, the site of
chronic liver disease, using single-cell RNA sequencing in order to study the
heterogeneity and complexity of the tumor, to identify novel therapeutic targets and
tumor phenotypes that correlate with response to treatment.
Patient-derived preclinical models, developed at unit UMR_S1110, will allow us to better
understand the biology of chronic liver disease and liver tumors at the patient level,
identify the most appropriate treatment for the patient, and evaluate new treatments and
biomarkers to non-invasively diagnose the onset of liver disease, for the benefit of
personalized medicine for the benefit of the patient.
Blood samples obtained from patients with chronic liver disease will also allow us to:
- Advance knowledge on viral hepatitis, in particular HCV, HBV and HDV;
- Implement new strategies for the development of a vaccine for HCV;
- Identify new biomarkers of hepatic carcinogenesis by comparing the metabolomic and
inflammatory profiles of patients.
The partnership between Inserm, the University of Strasbourg and the University Hospitals of
Strasbourg makes it possible to create unique synergies that will ultimately help identify
new targets for therapeutic and preventive strategies against these diseases which represent
a major public health problem.
